Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 January 2025

View source ↗

Summary

The EMA's Pharmacovigilance Risk Assessment Committee discussed an investigation into a rare eye condition potentially associated with semaglutide medicines and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• OZEMPIC (semaglutide)
• Rybelsus (semaglutide)
• WEGOVY (Semaglutide)

Snippet

Investigation of risk of rare eye condition with semaglutide medicines